Those living with HIV will be able to take fewer medication.
A new drug to be used for the treatment of HIV has launched in the UK today. The drug, Juluca, is the first single pill available for treatment of the lentivirus, and is also the smallest complete treatment available for people living with the condition.
It is hoped that the drug will lessen the burden of those taking daily medication, as it will allow those prescribed to take fewer individual medication.
Modern treatment and medical advances mean that those living with HIV are healthier and living longer than ever before. However, a lifetime of treatment can expose users to ongoing side-effects that can have an impact on their quality of life.
To coincide with the launch of the new drug, a new awareness campaign from ViiV Healthcare hopes to highlight just how ‘HIV has changed’. The campaign will help educate people on how those living with HIV can lead a healthy and prosperous life.
As part of the campaign, a new video highlights the evolution of HIV treatment with two people, Paida and George, sharing their own personal stories on living with HIV.
Clinical trials of Juluca found that the drug is as effective as the current standard of care and is a potential treatment option to support people living with HIV who are now growing old.
At the beginning of last year, John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare, said of the clinical trials:
The results from these studies may change our understanding of how HIV can be managed. For more than 20 years we thought that three or more drugs were required to maintain virologic suppression … These data mark an exciting first step towards making two drug regimens a reality in HIV treatment.
The drug is available to those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) and have been on a stable antiretroviral regimen for at least six months without side effects or complications.
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline and Pfizer dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV.